Neuregulin: An Oligodendrocyte Growth Factor Absent in Active Multiple Sclerosis Lesions
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) which results in demyelination and axonal injury. Conventional therapy for MS is immune suppression in the absence of agents that promote neural and glial survival or remyelination. Neuregulins are a family of ligands that exert trophic effects on both neurons and glia. Using mice bearing a null mutation in the neuregulin gene, here we demonstrate that neuregulins are necessary for the normal development of oligodendrocytes. In addition, neuregulins are produced in the normal human CNS by astrocytes as well as neurons. Astrocyte-derived neuregulin is functionally active in bioassays and exists in secreted and membrane-associated β-isoforms. In active and chronic active MS lesions, however, the expression of astrocyte neuregulin is dramatically reduced. The absence of neuregulin in active MS lesions may contribute to the paucity of remyelination in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
The erbB3 gene product is a receptor for heregulin.
Carraway, K. L., Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., & Cerione, R. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36789-3 · Cited by 362
Cited by
Neuregulins: functions, forms, and signaling strategies
Falls, D. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00102-7 · Cited by 1,071
Why does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
Axonal regulation of myelination by neuregulin 1
Nave, K.-A., & Salzer, J. L. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.08.008 · Cited by 452
The EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 397
Neuregulin and BDNF Induce a Switch to NMDA Receptor-Dependent Myelination by Oligodendrocytes
Lundgaard, I., Luzhynskaya, A., Stockley, J. H., Wang, Z., Evans, K. A., Swire, M., Volbracht, K., Gautier, H. O. B., Franklin, R. J. M., ffrench-Constant, C., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001743 · Cited by 339
Efficient Generation of Astrocytes from Human Pluripotent Stem Cells in Defined Conditions
Shaltouki, A., Peng, J., Liu, Q., Rao, M. S., & Zeng, X. (2013) · Stem Cells · doi:10.1002/stem.1334 · Cited by 267
Armstrong, R. C., Le, T. Q., Frost, E. E., Borke, R. C., & Vana, A. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08574.2002 · Cited by 178
“This inhibition may be especially detrimental in MS lesions that may also have reduced influence of differentiation promoting growth factors, such as the decreased neuregulin expression reported in MS lesions (Viehover et al., 2001).”
BackgroundRemyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Endogenous cell repair of chronic demyelination
Armstrong, R. C., Le, T. Q., Flint, N. C., Vana, A. C., & Zhou, Y.-X. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000205142.08716.7e · Cited by 125
Platelet-Derived Growth Factor Promotes Repair of Chronically Demyelinated White Matter
Vana, A. C., Flint, N. C., Harwood, N. E., Le, T. Q., Fruttiger, M., & Armstrong, R. C. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181587d46 · Cited by 101
“However, MS lesions may have increased expression of signals that inhibit differentiation (48, 49) or variable expression of molecules that support newly generated oligodendrocytes to survive and myelinate viable axons (50, 51).”
BackgroundRemyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Metadata
- Authors
- Viehover, A., Miller, R. H., Park, S.-K., Fischbach, G., & Vartanian, T.
- Venue
- Developmental Neuroscience
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 23
- Issue
- 4-5
- Pages
- 377-386
- ISSN
- 0378-5866 (ISSN-L)
- 1421-9859
- OpenAlex
- W2072959439
- Cited by
- 74
- References
- 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.